Midwest Trust Co Makes New Investment in Fresenius Medical Care AG & Co. KGaA $FMS

Midwest Trust Co purchased a new stake in Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) during the second quarter, HoldingsChannel.com reports. The fund purchased 9,861 shares of the company’s stock, valued at approximately $282,000.

Several other large investors also recently made changes to their positions in the stock. Brooklyn Investment Group raised its holdings in shares of Fresenius Medical Care AG & Co. KGaA by 424.5% during the first quarter. Brooklyn Investment Group now owns 1,285 shares of the company’s stock worth $32,000 after acquiring an additional 1,040 shares during the period. Atlantic Union Bankshares Corp bought a new position in Fresenius Medical Care AG & Co. KGaA during the 2nd quarter worth about $43,000. Hantz Financial Services Inc. raised its stake in shares of Fresenius Medical Care AG & Co. KGaA by 568.5% in the 2nd quarter. Hantz Financial Services Inc. now owns 2,079 shares of the company’s stock valued at $59,000 after purchasing an additional 1,768 shares during the period. Huntington National Bank lifted its holdings in shares of Fresenius Medical Care AG & Co. KGaA by 219.5% in the second quarter. Huntington National Bank now owns 2,355 shares of the company’s stock valued at $67,000 after purchasing an additional 1,618 shares in the last quarter. Finally, Russell Investments Group Ltd. lifted its holdings in shares of Fresenius Medical Care AG & Co. KGaA by 33.3% in the first quarter. Russell Investments Group Ltd. now owns 4,200 shares of the company’s stock valued at $105,000 after purchasing an additional 1,049 shares in the last quarter. Institutional investors own 8.37% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts recently issued reports on the company. Wall Street Zen downgraded Fresenius Medical Care AG & Co. KGaA from a “strong-buy” rating to a “buy” rating in a report on Saturday, November 8th. Morgan Stanley reaffirmed an “underweight” rating on shares of Fresenius Medical Care AG & Co. KGaA in a research note on Tuesday, August 12th. Weiss Ratings upgraded shares of Fresenius Medical Care AG & Co. KGaA from a “hold (c+)” rating to a “buy (b-)” rating in a report on Wednesday, October 8th. UBS Group cut shares of Fresenius Medical Care AG & Co. KGaA from a “sell” rating to an “underperform” rating in a report on Wednesday, October 15th. Finally, Bank of America downgraded shares of Fresenius Medical Care AG & Co. KGaA from a “neutral” rating to an “underperform” rating in a research report on Wednesday, October 15th. One investment analyst has rated the stock with a Buy rating, two have issued a Hold rating and three have assigned a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Reduce” and a consensus price target of $30.00.

Fresenius Medical Care AG & Co. KGaA Trading Down 0.2%

NYSE FMS opened at $23.94 on Thursday. The company has a market cap of $14.05 billion, a PE ratio of 19.62, a PEG ratio of 0.64 and a beta of 0.90. The company has a current ratio of 1.44, a quick ratio of 1.08 and a debt-to-equity ratio of 0.44. Fresenius Medical Care AG & Co. KGaA has a 12 month low of $21.06 and a 12 month high of $30.46. The stock has a 50 day moving average of $25.93 and a 200-day moving average of $26.58.

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) last issued its earnings results on Tuesday, November 4th. The company reported $0.64 earnings per share for the quarter, topping analysts’ consensus estimates of $0.59 by $0.05. Fresenius Medical Care AG & Co. KGaA had a net margin of 3.39% and a return on equity of 6.75%. The business had revenue of $5.63 billion for the quarter, compared to the consensus estimate of $4.72 billion. On average, equities research analysts anticipate that Fresenius Medical Care AG & Co. KGaA will post 1.51 EPS for the current fiscal year.

Fresenius Medical Care AG & Co. KGaA Company Profile

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.